abstract |
The present invention relates to a method of treating migraine in a mammal, including a human, by administering to the mammal a 5HT 1 receptor agonist in combination with caffeine and a cyclooxygenase-2 (COX-2) inhibitor. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a 5HT 1 receptor agonist with caffeine a cyclooxygenase-2 (COX-2) inhibitor. |